Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 13/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456703 | 0.88 | DRD2 (0.40) | PREPDPP4DPP8DPP9PTGS2 | |
| SCHEMBL2854018 | 0.83 | PREP (0.39) | PREPDPP4DPP8DPP9PTGS2 | |
| SCHEMBL2855851 | 0.83 | GPR119 (0.42) | PREPDPP4KDM5AHSD17B10TGM2 | |
| SCHEMBL2852502 | 0.82 | USP30 (0.39) | PREPDPP4DPP8DPP9PTGS2 | |
| SCHEMBL2710385 | 0.82 | DPP4 (0.45) | PREPDPP4DPP8DPP9PTGS2 | |
| SCHEMBL2710642 | 0.82 | PREP (0.50) | PREPDPP4DPP8DPP9HSD17B10 | |
| SCHEMBL2725905 | 0.81 | HSD17B10 (0.52) | PREPDPP4HSD17B10 | |
| SCHEMBL2709609 | 0.81 | PREP (0.50) | PREPDPP4DPP8DPP9HSD17B10 | |
| SCHEMBL2711676 | 0.80 | DPP4 (0.46) | PREPDPP4GPR119 | |
| SCHEMBL2708268 | 0.80 | PREP (0.43) | PREPDPP4DPP8DPP9HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790725-B2 | Thiazolidine derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-07 | — | — | US | disclosed |
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1426366-A1 | THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259880-A1 | THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF | DPP4, DPP7, DPP3 | PREP 391/4885DPP4 1/4885DPP8 5/4885 |
| US-20040259883-A1 | Thiazolidine derivative and medicinal use thereof | DPP4, DPP7, DPP3 | PREP 487/4885DPP4 1/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.